Erasca, Inc. (ERAS) Cash Flow Statement

The gap between net income and operating cash flow is driven primarily by stock-based compensation, which totaled $9.6M in 2026Q2, and a one-time $183.4M loss in 2026Q1 that appears non-cash. Excluding that outlier, OCF/NI ratios hover near 0.6-0.8, suggesting recurring cash burn is more stable than headline losses imply. Investors should focus on cash burn rather than net income, as the latter includes significant non-cash charges that do not affect liquidity.

FCF has been remarkably consistent, ranging from -$20.6M to -$33.3M, with no quarter showing improvement, reflecting a pre-revenue stage where spending is tied to trial execution. The 2026Q1 spike in net loss did not translate to higher cash burn, confirming the non-cash nature of that charge. Without a partnership or financing, this trajectory suggests the company will exhaust its $73.8M cash within two to three quarters.

CapEx is immaterial, never exceeding $83K in any quarter, which indicates the company relies on outsourced manufacturing and leased lab space rather than owning heavy assets. This low capital intensity means the primary cash drain is R&D labor and trial costs, not fixed asset investment. The absence of meaningful CapEx also implies no depreciation shield, so cash burn closely tracks operating expenses.

WC changes ranged from -$6.1M to +$6.0M, indicating that clinical trial accruals and vendor payment timing can shift cash flow by roughly 20% of quarterly burn. The positive swing in 2026Q2 likely reflects delayed payments or reduced receivables, but this is not a sustainable source of liquidity. Investors should monitor whether the company is stretching payables, as that could signal financial strain.

The complete absence of capital returns or M&A underscores a survival-focused strategy where cash preservation is paramount. Management appears to be prioritizing pipeline advancement over shareholder distributions, which is typical for a clinical-stage biotech. The lack of deployment also means the only potential source of future value is successful drug development, not financial engineering.

The divergence between accounting losses and cash reality is substantial, with non-cash items accounting for nearly half of reported losses. This suggests that while the company is burning cash at a concerning rate, the actual liquidity drain is less severe than the income statement implies. However, the $73.8M cash balance still appears insufficient for more than two quarters of operations, making dilution or partnership essential.